Application of Liposomal Doxorubicin in the Treatment of Refractory Non-Hodgkin’s Lymphoma
- VernacularTitle:多柔比星脂质体在难治性非霍奇金淋巴瘤治疗中的应用
- Author:
Huifang JIANG
;
Yinjun LOU
;
Wenyuan MAI
;
Jie JIN
- Publication Type:Journal Article
- Keywords:
Liposomal doxorubicin;
Non-Hodgkin’s lymphoma refraltory
- From:
Journal of Medical Research
2006;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of liposomal doxorubicin combined with cyclophosphamide, vincristine and prednisone in the treatment of refractory Non-Hodgkin’s lymphoma.Methods Liposomal doxorubicin (40mg/m2) was given by intravenous drip in the 1st day. Cyclophosphamide (750mg/m2) was given by intravenous injection in the 1st day. Vincristine (2mg) was given by intravenous injection in the 1st day. Prednisone (100mg/m2) was given orally from the 1st to the 5th day. A cycle was repeated every 3 to 4 weeks. Every patient took at least 2 cycles of the regimen.Results A total of 13 patients were assessed in the group. Among them, 7 were completely release (53.8), 4 were partially release (30.67) and 2 remained the same (15.35). The B symptom of 7 patients in the 9 with that disappeared, and that of the other 2 patients was improved obviously. The most common adverse effects were slight gastrointestinal reactions and the grade Ⅲ bone marrow suppression in a few patients. Conclusion The regimen of liposomal doxorubicin combined with cyclophosphamide, vincristine and prednisone is effective in the treatment of refractory Non-Hodgkin’s lymphoma with tolerable toxicity. It may be a salvage chemotherapeutic regimen deserving further study.
